Twist Bioscience Reports Strong Q2 Revenue Growth, Details Strategic Acquisition and Litigation Settlement
Summary
Twist Bioscience reported strong Q2 revenue growth and improved gross margins, alongside increased net losses and cash burn, but affirmed over a year of liquidity. The filing also detailed a strategic acquisition and a litigation settlement.
Key Events
-
Q2 Financial Performance
Revenue increased 19.3% to $110.7 million for the three months ended March 31, 2026, with gross margin improving to 51.6%. However, the net loss widened to $44.0 million, and loss from operations increased to $45.9 million.
-
Liquidity and Cash Runway
Cash and cash equivalents, along with short-term investments, decreased to $171.7 million as of March 31, 2026. Despite this, management expects current funds to be sufficient for operations for at least one year.
-
Strategic Invenra Acquisition
The company entered a license agreement and acquired a 6.24% equity interest in Invenra Inc. for a total commitment of $33.8 million. This was primarily settled through the issuance of common stock ($20.0 million for the license, $13.8 million for equity), limiting cash outflow.
-
Litigation Settlement
A $17.1 million settlement in principle was reached for a securities class action lawsuit, with the majority of the liability expected to be funded by the company's insurance carriers.
Analysis
Twist Bioscience's latest 10-Q filing provides a comprehensive look at its Q2 2026 performance, following the earlier 8-K release of headline figures. While the company demonstrated robust revenue growth and improved gross margins, it also reported increased net losses and a notable cash burn from operations. A key positive is management's assertion of having at least one year of liquidity runway. The filing also details a significant strategic acquisition of Invenra's antibody discovery platform, largely settled with common stock to preserve cash, and the settlement of a securities class action lawsuit, with most costs expected to be covered by insurance. These detailed disclosures offer crucial insights into the company's operational progress, strategic direction, and risk management.
At the time of this filing, TWST was trading at $56.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $23.30 to $66.06. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.